Abbott Gets FDA, CE Clearance for AI-Guided Ultreon 3.0

Abbott Laboratories (ABT) received U.S. FDA clearance and CE Mark for Ultreon 3.0, an AI-powered optical coherence tomography (OCT) platform. The system integrates high-resolution coronary imaging with automated insights to guide stent sizing and placement in complex percutaneous coronary interventions.

The Product

Ultreon 3.0 is an OCT platform that uses artificial intelligence to provide automated analysis of coronary images, helping physicians assess vessel size, select the appropriate stent, and determine optimal placement. The technology aims to make OCT a more intuitive and workflow-friendly tool.

Pricing and Availability

Abbott has not disclosed pricing details. The platform will be available in U.S. and European markets following regulatory clearances.

Competition

Ultreon 3.0 faces competition from other OCT systems such as those from Boston Scientific, as well as alternative imaging technologies like IVUS (intravascular ultrasound). However, Ultreon 3.0's AI integration may reduce procedure time and improve accuracy.

Potential Impact on the Company

Ultreon 3.0 is expected to strengthen Abbott's position in the cardiovascular device market, particularly in complex coronary interventions. Adoption of the technology could drive demand for related stent products, supporting revenue growth in the segment.